Bruni D, K Angell H and Galon J
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Nature Reviews Cancer
doi: 10.1038/s41568-020-0285-7
https://www.nature.com/articles/s41568-020-0285-7
O’Connor JM, Esteso F & Chacón M
Official French SARS-CoV-2 guidelines for cancer patients, a triage solution with precision medicine
Future Medicine
Colorectal Cancer | Ahead of Print
https://www.futuremedicine.com/doi/10.2217/crc-2020-0018
Blair H
Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer
Molecular Diagnosis & Therapy volume
24, pages365–370(2020)
https://link.springer.com/article/10.1007/s40291-020-00459-6
Marliot F, Chen X, Kirilovsky A et al.
Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer
BMJ
http://dx.doi.org/10.1136/jitc-2019-000272
https://jitc.bmj.com/content/8/1/e000272
Sinicrope F, Shi Q, Hermitte F et al.
Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer
JNCI Cancer Spectrum
Volume 4, Issue 3, June 2020, pkaa023
https://academic.oup.com/jncics/article/4/3/pkaa023/5812786
Pages F, Andre T, Taieb J et al.
Prognostic and Predictive Value of the Immunoscore in Stage III Colon Cancer Patients Treated With Oxaliplatin in the Prospective IDEA France PRODIGE-GERCOR Cohort Study
Annals of Oncology
PMID: 32294529
https://pubmed.ncbi.nlm.nih.gov/32294529/
Pages F, Andre T, Taieb J et al.
Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)
Journal of Clinical Oncology
Volume 37, Issue 15_suppl
https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3513
Galon J & Bruni D
Tumor Immunology and Tumor Evolution: Intertwined Histories
Immunity
https://doi.org/10.1016/j.immuni.2019.12.018
https://www.cell.com/immunity/fulltext/S1074-7613(19)30537-0
Galon J & Bruni D
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.
Nat Rev Drug Discov.
18(3):197-218
https://www.ncbi.nlm.nih.gov/pubmed/30610226
Mlecnik B, Bindea G, Angell HK et al.
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.
Immunity
44(3):698-711
https://www.ncbi.nlm.nih.gov/pubmed/26982367
Galon J, Costes A, Sanchez-Cabo F et al.
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
Science
313(5795):1960-4
https://www.ncbi.nlm.nih.gov/pubmed/17008531
Pagès F, Kirilovsky A, Mlecnik B et al.
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.
J Clin Oncol.
27(35):5944-51
https://www.ncbi.nlm.nih.gov/pubmed/19858404
Mlecnik B, Tosolini M, Kirilovsky A et al.
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.
J Clin Oncol.
29(6):610-8
https://www.ncbi.nlm.nih.gov/pubmed/21245428
Kirilovsky A, Marliot F, El Sissy C et al.
Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.
Int Immunol.
28(8):373-82
https://www.ncbi.nlm.nih.gov/pubmed/27121213
Pagès F, Mlecnik B, Marliot F et al.
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
Lancet
391 (10135)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30789-X/fulltext
Sinicrope F, Shi Q, Hermitte F et al.
Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).
J Clin Oncol.
35:15s (suppl; abstr 3579)
https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.3579
Sinicrope F, Shi Q, Hermitte F et al.
Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).
J Clin Oncol.
36:4s (suppl; abstr 614)
https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.614
Angelova M, Mlecnik B, Vasaturo A et al.
Evolution of Metastases in Space and Time under Immune Selection.
Cell
10.1016/j.cell.2018.09.018
https://www.cell.com/cell/fulltext/S0092-8674(18)31230-3
Fridman WH, Pagès F, Sautès-Fridman C, Galon J.
The immune contexture in human tumours: impact on clinical outcome.
Nat Rev Cancer.
12(4):298-306
https://www.ncbi.nlm.nih.gov/pubmed/22419253
Galon J, Angell HK, Bedognetti D, Marincola FM
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.
Immunity
39(1):11-26
https://www.ncbi.nlm.nih.gov/pubmed/23890060
Bindea G, Mlecnik B, Tosolini M et al.
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
Immunity
39(4):782-95
https://www.ncbi.nlm.nih.gov/pubmed/24138885
Berghoff AS, Fuchs E, Ricken G et al.
Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.
Oncoimmunology
5(1):e1057388
https://www.ncbi.nlm.nih.gov/pubmed/26942067
Mlecnik B, Bindea G, Kirilovsky A et al.
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.
Sci Transl Med.
8(327):327ra26
https://www.ncbi.nlm.nih.gov/pubmed/26912905
Galon J, Mlecnik B, Marliot F et al.
Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.
J Clin Oncol.
JCO.2016.34.15_suppl.3500
https://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.3500
Hermitte F
Biomarkers immune monitoring technology primer: Immunoscore® Colon.
Journal for ImmunoTherapy of Cancer
doi:10.1186/s40425-016-0161-x
https://jitc.biomedcentral.com/articles/10.1186/s40425-016-0161-x
Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G
The immune contexture in cancer prognosis and treatment.
Nat Rev Clin Oncol.
14(12):717-734
https://www.ncbi.nlm.nih.gov/pubmed/28741618
Mlecnik B, Van den Eynde M, Bindea G et al.
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
J Natl Cancer Inst.
1;110(1)
https://www.ncbi.nlm.nih.gov/pubmed/28922789
Angell HK, Bruni D, Barrett JC et al.
The Immunoscore: Colon Cancer and Beyond.
Clin Cancer Res.
doi: 10.1158/1078-0432
https://www.ncbi.nlm.nih.gov/pubmed/31413009
Zeitoun G, Sissy CE, Kirilovsky A et al.
The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.
Chirurgia (Bucur).
114(2):152-161
https://www.ncbi.nlm.nih.gov/pubmed/31060646
Mascaux C, Angelova M, Vasaturo A et al.
Immune evasion before tumour invasion in early lung squamous carcinogenesis.
Nature
571(7766):570-575
https://www.ncbi.nlm.nih.gov/pubmed/31243362